Skip to main content
Top
Published in: BMC Infectious Diseases 1/2010

Open Access 01-12-2010 | Research article

Regional differences in rates of HIV-1 viral load monitoring in Canada: Insights and implications for antiretroviral care in high income countries

Authors: Janet M Raboud, Mona R Loutfy, DeSheng Su, Ahmed M Bayoumi, Marina B Klein, Curtis Cooper, Nima Machouf, Sean Rourke, Sharon Walmsley, Anita Rachlis, P Richard Harrigan, Marek Smieja, Christos Tsoukas, Julio SG Montaner, Robert S Hogg, the CANOC Collaboration

Published in: BMC Infectious Diseases | Issue 1/2010

Login to get access

Abstract

Background

Viral load (VL) monitoring is an essential component of the care of HIV positive individuals. Rates of VL monitoring have been shown to vary by HIV risk factor and clinical characteristics. The objective of this study was to determine whether there are differences among regions in Canada in the rates of VL testing of HIV-positive individuals on combination antiretroviral therapy (cART), where the testing is available without financial barriers under the coverage of provincial health insurance programs.

Methods

The Canadian Observational Cohort (CANOC) is a collaboration of nine Canadian cohorts of HIV-positive individuals who initiated cART after January 1, 2000. The study included participants with at least one year of follow-up. Generalized Estimating Equation (GEE) regression models were used to determine the effect of geographic region on (1) the occurrence of an interval of 9 months or more between two consecutive recorded VL tests and (2) the number of days between VL tests, after adjusting for demographic and clinical covariates. Overall and regional annual rates of VL testing were also reported.

Results

3,648 individuals were included in the analysis with a median follow-up of 42.9 months and a median of 15 VL tests. In multivariable GEE logistic regression models, gaps in VL testing >9 months were more likely in Quebec (Odds Ratio (OR) = 1.72, p < 0.0001) and Ontario (OR = 1.78, p < 0.0001) than in British Columbia and among injection drug users (OR = 1.68, p < 0.0001) and were less likely among older individuals (OR = 0.77 per 10 years, p < 0.0001), among men having sex with men (OR = 0.62, p < 0.0001), within the first year of cART (OR = 0.15, p < 0.0001), among individuals on cART at the time of the blood draw (OR = 0.34, p < 0.0001) and among individuals with VL < 50 copies/ml at the previous visit (OR = 0.56, p < .0001).

Conclusions

Significant variation in rates of VL testing and the probability of a significant gap in testing were related to geographic region, HIV risk factor, age, year of cART initiation, type of cART regimen, being in the first year of cART, AIDS-defining illness and whether or not the previous VL was below the limit of detection.
Literature
1.
go back to reference Hammer SM, Eron JJ, Reiss P, Schooley RT, Thompson MA, Walmsley S, Cahn P, Fisch MA, Gatell JM, Hirsch MS, Jacobsen DM, Montaner JS, Richman DD, Yeni PG, Volberding PA, International AIDS Society - USA: Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA. 2008, 300: 555-70. 10.1001/jama.300.5.555.CrossRefPubMed Hammer SM, Eron JJ, Reiss P, Schooley RT, Thompson MA, Walmsley S, Cahn P, Fisch MA, Gatell JM, Hirsch MS, Jacobsen DM, Montaner JS, Richman DD, Yeni PG, Volberding PA, International AIDS Society - USA: Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA. 2008, 300: 555-70. 10.1001/jama.300.5.555.CrossRefPubMed
2.
go back to reference Moore DM, Awor A, Downing R, Kaplan J, Montaner JS, Hancock J, Were W, Mermin J: CD4+ T-cell monitoring does not accurately identify HIV-infected adults with virologic failure receiving antiretroviral therapy. J Acquir Immune Defic Syndr. 2008, 49: 477-84. 10.1097/QAI.0b013e318186eb18.CrossRefPubMed Moore DM, Awor A, Downing R, Kaplan J, Montaner JS, Hancock J, Were W, Mermin J: CD4+ T-cell monitoring does not accurately identify HIV-infected adults with virologic failure receiving antiretroviral therapy. J Acquir Immune Defic Syndr. 2008, 49: 477-84. 10.1097/QAI.0b013e318186eb18.CrossRefPubMed
3.
go back to reference Hirsch MS, Gunthard HF, Schapiro M, Brun-Vezinet F, Clotet B, Hammer SM, Johnson VA, Kuritzkes DR, Mellors JW, Pillay D, Yeni PG, Jacobsen DM, Richman DD: Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society- USA panel. Clin Infect Dis. 2008, 47: 266-85. 10.1086/589297.CrossRefPubMed Hirsch MS, Gunthard HF, Schapiro M, Brun-Vezinet F, Clotet B, Hammer SM, Johnson VA, Kuritzkes DR, Mellors JW, Pillay D, Yeni PG, Jacobsen DM, Richman DD: Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society- USA panel. Clin Infect Dis. 2008, 47: 266-85. 10.1086/589297.CrossRefPubMed
4.
go back to reference Wilson D, Keiluhu AK, Kogrum S, Reid T, Seriratana N, Ford N, Kyawkyaw M, Talangsri P, Taochalee N: HIV-1 viral load monitoring: an opportunity to reinforce treatment adherence in a resource-limited setting in Thailand. Trans R Soc Trop Med Hyg. 2009, 103: 601-6. 10.1016/j.trstmh.2008.11.007.CrossRefPubMed Wilson D, Keiluhu AK, Kogrum S, Reid T, Seriratana N, Ford N, Kyawkyaw M, Talangsri P, Taochalee N: HIV-1 viral load monitoring: an opportunity to reinforce treatment adherence in a resource-limited setting in Thailand. Trans R Soc Trop Med Hyg. 2009, 103: 601-6. 10.1016/j.trstmh.2008.11.007.CrossRefPubMed
5.
go back to reference Raboud JM, Abdurrahman ZB, Major C, Millson P, Robinson G, Rachlis A, Bayoumi AM: Nonfinancial factors associated with decreased plasma viral load testing in Ontario, Canada. J Acquir Immune Defic Syndr. 2005, 39: 327-32. 10.1097/01.qai.0000143603.94728.b2.CrossRefPubMed Raboud JM, Abdurrahman ZB, Major C, Millson P, Robinson G, Rachlis A, Bayoumi AM: Nonfinancial factors associated with decreased plasma viral load testing in Ontario, Canada. J Acquir Immune Defic Syndr. 2005, 39: 327-32. 10.1097/01.qai.0000143603.94728.b2.CrossRefPubMed
6.
go back to reference Laine C, Zhang D, Hauck WW, Turner BJ: HIV-1 RNA viral load monitoring in HIV-infected drug users on antiretroviral therapy; relationship with outpatient care patterns. J Acquir Immune Defic Syndr. 2002, 29: 270-4.CrossRefPubMed Laine C, Zhang D, Hauck WW, Turner BJ: HIV-1 RNA viral load monitoring in HIV-infected drug users on antiretroviral therapy; relationship with outpatient care patterns. J Acquir Immune Defic Syndr. 2002, 29: 270-4.CrossRefPubMed
7.
go back to reference Druyts EF, Yip B, Lima VD, Burke TA, Lesovski D, Fernandes KA, McInnes CW, Rustad CA, Montaner JSG, Hogg RS: Health care services utilization stratified by virological and immunological markers of HIV: evidence from a universal health care setting. HIV Medicine. 2009, 10: 88-93. 10.1111/j.1468-1293.2008.00656.x.CrossRefPubMed Druyts EF, Yip B, Lima VD, Burke TA, Lesovski D, Fernandes KA, McInnes CW, Rustad CA, Montaner JSG, Hogg RS: Health care services utilization stratified by virological and immunological markers of HIV: evidence from a universal health care setting. HIV Medicine. 2009, 10: 88-93. 10.1111/j.1468-1293.2008.00656.x.CrossRefPubMed
8.
go back to reference Palmer AK, Klein MB, Raboud JM, Cooper C, Loutfy M, Machouf N, Montaner JSG, Rourke SB, Smieja M, Tsoukas C, Yip B, Milan D, Hogg RS, the CANOC Collaboration: Cohort Profile: The Canadian Observational Cohort (CANOC) Collaboration. International Journal of Epidemiology. Palmer AK, Klein MB, Raboud JM, Cooper C, Loutfy M, Machouf N, Montaner JSG, Rourke SB, Smieja M, Tsoukas C, Yip B, Milan D, Hogg RS, the CANOC Collaboration: Cohort Profile: The Canadian Observational Cohort (CANOC) Collaboration. International Journal of Epidemiology.
9.
go back to reference Zeger SL, Liang KY: Longitudinal data analysis for discrete and continuous outcomes. Biometrics. 1986, 42: 121-30. 10.2307/2531248.CrossRefPubMed Zeger SL, Liang KY: Longitudinal data analysis for discrete and continuous outcomes. Biometrics. 1986, 42: 121-30. 10.2307/2531248.CrossRefPubMed
10.
go back to reference Lima V, Harrigan R, Montaner JSG: Increased reporting of detectable plasma HIV-1 RNA levels at the critical threshold of 50 copies per milliliter with the Taqman assay in comparison to the Amplicor assay. J Acquir Immune Defic Syndr. 2009, 51: 3-6. 10.1097/QAI.0b013e31819e721b.CrossRefPubMed Lima V, Harrigan R, Montaner JSG: Increased reporting of detectable plasma HIV-1 RNA levels at the critical threshold of 50 copies per milliliter with the Taqman assay in comparison to the Amplicor assay. J Acquir Immune Defic Syndr. 2009, 51: 3-6. 10.1097/QAI.0b013e31819e721b.CrossRefPubMed
11.
go back to reference Smit E, Bhattacharya S, Osman H, Taylor S: Increased Frequency of HIV-1 Viral Load Blip Rate Observed After Switching from Roche Cobas Amplicor to Coas Taqman Assay. J Acquir Immune Deficiency Syndr. 2009, 51: 364-5. 10.1097/QAI.0b013e3181aa13b3.CrossRef Smit E, Bhattacharya S, Osman H, Taylor S: Increased Frequency of HIV-1 Viral Load Blip Rate Observed After Switching from Roche Cobas Amplicor to Coas Taqman Assay. J Acquir Immune Deficiency Syndr. 2009, 51: 364-5. 10.1097/QAI.0b013e3181aa13b3.CrossRef
12.
go back to reference Reekie J, Mocroft A, Sambatakou H, Machala L, Chiesi A, van Lunzen J, Clumeck N, Kirk O, Gazzard B, Lundgren JD, the EuroSIDA study group: Does less frequent routine monitoring of patients on a stable, fully suppressed cART regimen lead to an increased risk of treatment failure?. AIDS. 2008, 22: 2381-2390. 10.1097/QAD.0b013e328317a6eb.CrossRefPubMed Reekie J, Mocroft A, Sambatakou H, Machala L, Chiesi A, van Lunzen J, Clumeck N, Kirk O, Gazzard B, Lundgren JD, the EuroSIDA study group: Does less frequent routine monitoring of patients on a stable, fully suppressed cART regimen lead to an increased risk of treatment failure?. AIDS. 2008, 22: 2381-2390. 10.1097/QAD.0b013e328317a6eb.CrossRefPubMed
13.
go back to reference Boulos D, Yan P, Schanzer D, Remis RS, Archibald CP: Estimates of HIV prevalence and incidence in Canada, 2005. Canada Communicable Disease Report. 2006, 32: 164-74. Boulos D, Yan P, Schanzer D, Remis RS, Archibald CP: Estimates of HIV prevalence and incidence in Canada, 2005. Canada Communicable Disease Report. 2006, 32: 164-74.
Metadata
Title
Regional differences in rates of HIV-1 viral load monitoring in Canada: Insights and implications for antiretroviral care in high income countries
Authors
Janet M Raboud
Mona R Loutfy
DeSheng Su
Ahmed M Bayoumi
Marina B Klein
Curtis Cooper
Nima Machouf
Sean Rourke
Sharon Walmsley
Anita Rachlis
P Richard Harrigan
Marek Smieja
Christos Tsoukas
Julio SG Montaner
Robert S Hogg
the CANOC Collaboration
Publication date
01-12-2010
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2010
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/1471-2334-10-40

Other articles of this Issue 1/2010

BMC Infectious Diseases 1/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.